secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001104659-24-006019
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics receives FDA SPA agreement for NORSE EIGHT trial; announces up to $172M private placement
--------------------------------------------------------------------------------

- FDA agreed under SPA to NORSE EIGHT non-inferiority trial (~400 wet AMD subjects); primary endpoint BCVA change at 8 weeks.
- Private placement of up to $60M in common stock plus warrants for up to $99M additional proceeds upon cash exercise.
- Existing note amended: maturity extended to July 1, 2025; conversion price reduction on $15M principal tied to qualified offering.
- Closing conditioned on stockholder approval of share increase, reverse split, and Nasdaq Rule 5635(d) approval; expected Q1 2024.
- Proceeds to fund NORSE EIGHT, other ONS-5010 development, working capital; BLA resubmission targeted by end of CY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/0001104659-24-006019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer